- 53.6% of adults who started a GLP-1 for overweight or obesity had stopped within a year, and 72.2% within two.1
- Without type 2 diabetes, 64.8% stopped within a year. With diabetes, 46.5% did.
- Of those who stopped, 36.3% without diabetes and 47.3% with diabetes started again within a year. Weight coming back made a restart more likely.
The study
Rodriguez and colleagues at Truveta looked at electronic health records of 125,474 adults in the United States who started liraglutide, semaglutide or tirzepatide between 2018 and 2023.1 About 61% of them also had type 2 diabetes.
Each person was followed for up to two years to see whether they stopped, and for two more years after stopping to see whether they started again.
Who stops more often
People without type 2 diabetes stopped more often than people with it. In both groups, moderate or severe stomach and gut side effects were linked to stopping, and losing more weight was linked to staying on treatment.1
Higher household income was linked to staying on treatment only in the group with diabetes.
The more weight people lost, the less likely they were to stop.
Coming back
Stopping was often not the end. Among people who stopped, a large share started again within a year, and the main signal in the data was the scale: weight regained after stopping was linked to a higher chance of restarting.1
What this means for your log
The study does not tell anyone whether to stay on a medication or stop. That is a decision for you and your prescriber. It does show which records are worth keeping.
Side effects are one. Writing down what you felt, and how many days after the shot, gives your prescriber something concrete to work with. The other is your weight after the last dose. If you stop, keep weighing in: regain shows up on the scale weeks before it shows up anywhere else.
Limits of the study
Health records show prescriptions and measurements, not reasons. The data cannot say whether someone stopped because of cost, supply, a side effect that was never written down, or because they reached their goal. The study covered adults in the United States treated in the health systems that share data with Truveta.
Sources
- Rodriguez et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349
Log your next shot in one tap.
Open Dose Insider